Shirvan Mitchell 4

4 · Silexion Therapeutics Corp · Filed Feb 23, 2026

AI-generated summary of this filing

Updated Feb 23, 2026

Silexion (SLXN) CSO Shirvan Mitchell Receives 49,726-Share Award

What Happened

Shirvan Mitchell, Chief Scientific Officer and Chief Development Officer of Silexion Therapeutics Corp (SLXN), received a grant of 49,726 restricted share units (RSUs) on Feb 20, 2026. The RSUs were fully vested and immediately settled into 49,726 ordinary shares. The reported acquisition price is $0.00 (award/settlement), so no cash was paid by the insider.

Key Details

Transaction date: 2026-02-20; Form 4 filed: 2026-02-23.
Transaction type/code: Award/Grant (A) — fully vested RSUs immediately settled for shares (per footnote F2).
Shares acquired: 49,726 ordinary shares at $0.00 (aggregate $0 reported).
Shares owned after transaction: not specified in the excerpt provided in this summary (filing includes holdings information but exact post-transaction total not shown here).
Notable footnotes:
- F1/F4: Reported share and option counts reflect adjustments for a 1-for-9 reverse split (Nov 29, 2024) and a 1-for-15 reverse split (Jul 29, 2025).
- F2: Grant approved by the board; RSUs were fully vested and immediately settled for underlying ordinary shares.
- F3: Certain holdings rows are included for informational purposes only.
Filing timeliness: Form filed three days after the transaction date (Feb 23, 2026); the filing shows the transaction and no late-filing notation is indicated in the provided details.

Context

This was an award/settlement of RSUs (not a purchase or sale). Awards settled into shares are typically compensation for services and do not necessarily signal an insider buying or selling for investment reasons.
Because the RSUs were fully vested and immediately settled, this reflects compensation realization rather than an exercise of options or an open-market trade.

Form 4

Period: 2026-02-20

CSO and CDO

Transactions

Holdings

Stock Option (right to buy Ordinary Shares)
[F3][F4]
Exercise: $907.71From: 2024-08-15Exp: 2032-06-07→ Ordinary Shares (478 underlying)
478

Footnotes (4)

[F1]The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflect adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively.
[F2]The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors.
[F3]There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
[F4]The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.

Signature

/s/ Mirit Horenshtein Hadar, Attorney-in-fact|2026-02-23

2 files